menu ☰
menu ˟

[Correspondence] Teriparatide vs risedronate for osteoporosis – Authors' reply

12 May 2018

Yair Liel stated that the VERO clinical trial1 results were of relatively minor clinical significance because of the nature of the active comparator used (risedronate) and because bone turnover markers were not measured, suggesting that the inferior anti-fracture efficacy in the risedronate group was not evaluated properly. He suggested that a clinically relevant comparison could be made between teriparatide and zoledronate, or between teriparatide and denosumab, given their superior effects on bone mineral density observed when compared with oral bisphosphonates.

Click here to view the full article which appeared in The Lancet